<DOC>
	<DOCNO>NCT01479530</DOCNO>
	<brief_summary>The rationale conduct study evaluate efficacy , tolerability , safety rasagiline compare placebo levodopa-treated Parkinson 's Disease ( PD ) Chinese patient motor fluctuation . Azilect® ( Rasagiline ) indicate treatment idiopathic PD monotherapy ( without levodopa ) adjunct therapy ( levodopa ) patient end dose fluctuation .</brief_summary>
	<brief_title>Azilect® ( Rasagiline ) Levodopa-treated Parkinson 's Patients With Motor Fluctuations China</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients idiopathic PD . Patients motor fluctuation average least 1 hour daily `` OFF '' state waking hour . Patients Modified Hoehn Yahr stage ≤3 `` ON '' state . Patients take optimised levodopa dopa decarboxylase inhibitor ( DDI ) therapy ; must stable least 14 day prior baseline . Patients receive least 3 daily dos levodopa 8 daily dos levodopa . Patients demonstrated ability keep accurate `` 24hour '' diary prior randomisation . Patients clinically significant unstable medical surgical condition would preclude his/her safe complete study participation . Patients clinically significant unstable vascular disease . Patients undergone neurosurgical intervention PD . Patients severe disable dyskinesia . Patients clinically significant psychiatric illness , include major depression , compromise ability provide consent participate fully study . Patients Mini Mental State Examination ( MMSE ) score ≤24 . Patients diagnosis melanoma history melanoma , suspicious lesion . Other inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Rasagiline</keyword>
	<keyword>Azilect</keyword>
	<keyword>Parkinson´s Disease</keyword>
	<keyword>Motor fluctuation</keyword>
</DOC>